Vontobel Holding Ltd. trimmed its stake in Tilray Inc (NASDAQ:TLRY – Free Report) by 17.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 194,765 shares of the company’s stock after selling 40,660 shares during the quarter. Vontobel Holding Ltd.’s holdings in Tilray were worth $343,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. Tidal Investments LLC raised its holdings in shares of Tilray by 36,687.0% in the first quarter. Tidal Investments LLC now owns 10,677,428 shares of the company’s stock worth $26,373,000 after acquiring an additional 10,648,403 shares during the last quarter. Vanguard Group Inc. increased its stake in Tilray by 3.5% in the first quarter. Vanguard Group Inc. now owns 3,525,160 shares of the company’s stock valued at $8,707,000 after purchasing an additional 117,891 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Tilray by 8.7% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,679,532 shares of the company’s stock valued at $6,699,000 after purchasing an additional 213,834 shares during the last quarter. Bank of Montreal Can increased its stake in Tilray by 19.6% in the second quarter. Bank of Montreal Can now owns 2,169,100 shares of the company’s stock valued at $3,622,000 after purchasing an additional 355,778 shares during the last quarter. Finally, Swiss National Bank increased its stake in Tilray by 3.6% in the first quarter. Swiss National Bank now owns 1,490,938 shares of the company’s stock valued at $3,683,000 after purchasing an additional 51,700 shares during the last quarter. 9.35% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Roth Mkm dropped their target price on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research note on Friday, October 11th.
Tilray Price Performance
Shares of NASDAQ TLRY opened at $1.71 on Wednesday. Tilray Inc has a 1-year low of $1.45 and a 1-year high of $2.97. The business has a 50-day moving average of $1.73 and a 200-day moving average of $1.80. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -6.33 and a beta of 2.13.
Tilray (NASDAQ:TLRY – Get Free Report) last issued its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $200.00 million during the quarter, compared to the consensus estimate of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. Tilray’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.10) earnings per share. On average, equities analysts anticipate that Tilray Inc will post -0.14 EPS for the current fiscal year.
Tilray Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Featured Articles
- Five stocks we like better than Tilray
- What is a Low P/E Ratio and What Does it Tell Investors?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Pros And Cons Of Monthly Dividend Stocks
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.